Clinical research
The company announced a Phase III cardiac drug failed to meet its primary endpoint and a significant shift in its R&D efforts that have resulted in the termination of 75% of its staff.
Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.
NovoCure and Roche aim to explore the combined efficacy of TTFields with atezolizumab as a potential treatment for pancreatic cancer.
Zabdeno, a two-dose heterologous vaccine, was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.
The Phase II study showed enhanced immune memory response to the virus in 96% of vaccinated subjects, all of whom were exposed to an environment dominated by the delta variant.
BeiGene plans to describe the power of its lung cancer portfolio at the European Society for Medical Oncology Congress 2021. The conference will run from September 16-21.
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
PRESS RELEASES